Rockstar Lunch – Hosted by WEST

Are you looking for an opportunity to network with local senior leaders? If so, this is THE event for you. Join Laura Sepp-Lorenzino, Chief Scientific Officer at Intellia Therapeutics and Shelia Violette, Co-founder, Chief Scientific Officer, and President of Research Q32 Bio for an engaging conversation. Registration is for WEST MEMBERS ONLY and will be limited to a maximum of 25 participants to ensure an intimate experience.

ABOUT THE ROCKSTARS

Laura Sepp-Lorenzino, Ph.D. oversees Research and Early Development at  Intellia Therapeutics in her role as Chief Scientific Officer. Intellia’s leading CRISPR/Cas9-based platform supports a full-spectrum strategy, which deploys differentiated, modular solutions across in vivo and ex vivo therapeutic applications. Before joining Intellia, Laura was VP, Head of Nucleic Acid Therapies and member of the External Innovation team at Vertex Pharmaceuticals, with previous positions as VP and entrepreneur-in-residence at Alnylam Pharmaceuticals, Inc., and Executive Director RNA Therapeutics at Merck & Co., Inc. In addition to her extensive experience in nucleic acid therapies, Laura has expertise in oncology drug discovery and development acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as an assistant attending molecular biologist at Memorial Sloan-Kettering Cancer Center. She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. Laura is a member of the board of directors of Taysha Gene Therapies, the Alliance for Regenerative Medicine and the Oligonucleotide Therapeutics Society, and sits on the scientific advisory board of Thermo Fisher Scientific, Zymergen Inc., and the U.K. Nucleic Acid Therapy Accelerator.

Shelia Violette is a scientific leader in the field of inflammation, autoimmunity and fibrosis with depth of industry experience in translational research and drug development. Proven success initiating and advancing programs from early research through clinical development. Strong leadership skills, with strength in setting research strategy for multi-disciplinary teams of scientists and academic collaborators.